加载中
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
常规交易时段
US$0.4681
−US$0.0052 · -1.10%
盘中时间采用ET。市场数据可能有所延迟。
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
日内区间
当前US$0.4681
52周区间
当前US$0.4681
盘中时间采用ET。市场数据可能有所延迟。
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
日内区间
当前US$0.4681
52周区间
当前US$0.4681
营业利润
净利润
| 项目（CAD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 1331.4万 CAD | 1544.3万 CAD | 1334.92万 CAD | 1137.05万 CAD | 1292万 CAD |
| 销售、一般及管理费用 | 1541.1万 CAD | 1009.9万 CAD | 1181.89万 CAD | 817.86万 CAD | 1286.3万 CAD |
| 营业费用 | 2872.5万 CAD | 2554.2万 CAD | 2547.19万 CAD | 1983.79万 CAD | 2623.49万 CAD |
| 利息收入 | 52.96万 CAD | 119.9万 CAD | 132.6万 CAD | 52.8万 CAD | — |
| 折旧和摊销 | 7万 CAD | 8.7万 CAD | 30.38万 CAD | 28.88万 CAD | 45.2万 CAD |
| 营业利润 | −2872.5万 CAD | −2554.2万 CAD | −2547.19万 CAD | −1983.79万 CAD | −2623.49万 CAD |
| 净利润 | −2875.9万 CAD | −2279.4万 CAD | −2091.96万 CAD | −1829.87万 CAD | −2630.4万 CAD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2018年5月25日 | 2:19 | — | — |
已生效 2018年5月25日
2:19
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
